Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Estudo prospectivo de suplementos nutracêuticos para apoiar o crescimento capilar em mulheres

10 de novembro de 2026 atualizado por: Nutraceutical Wellness Inc.

Um estudo prospectivo unicêntrico de suplementos nutracêuticos para apoiar o crescimento do cabelo em mulheres com queda de cabelo autopercebida

A single site open label interventional study evaluating currently marketed hair supplements targeting the underlying root causes of thinning hair.

Visão geral do estudo

Status

Concluído

Condições

Intervenção / Tratamento

Descrição detalhada

A single site open label interventional study evaluating currently marketed hair supplements targeting the underlying root causes of thinning hair. All treatment regimens are commercially available nutraceutical hair growth supplements. 45 subjects will be enrolled into each of the 4 supplement groups. Subjects will undergo a baseline, baseline + 48 hours, 90 day, 90 day + 48 hours, 180 day and 180 day + 48 hours visit and will have compliance phone calls at Days 45 and 135. All subject data will be compared to baseline in paired comparison for each subject using a historical control.

Tipo de estudo

Intervencional

Inscrição (Real)

181

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • California
      • Sacramento, California, Estados Unidos, 95815
        • Integrative Skin Science and Research

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 70 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Sim

Gêneros Elegíveis para o Estudo

Fêmea

Descrição

Inclusion Criteria:

  1. Females of all Fitzpatrick skin, and hair types between 18-70 years of age with self-perceived thinning, confirmed by a dermatologist.
  2. Willing and able to adhere to the same dietary lifestyles for the duration of the study.
  3. Able to understand and sign an informed consent agreement and photo release form approved by the Institutional Review Board
  4. General good health, as determined by the Investigator or qualified sub-investigator.
  5. Willing and able to attend all study visits and comply with the test product daily instructions.
  6. Willing to use a mild non-medicated shampoo and conditioner for the duration of the study (medicated shampoo and conditioner refer to any prescription shampoo or conditioner as well as any over-the counter medicated shampoo or conditioner, such as those for treatment of dandruff or promoting hair growth).
  7. Willing and able to cooperate with the requirements of the study.
  8. Able to complete and understand the various questionnaires.

Exclusion Criteria:

  1. Individuals who are pregnant, planning a pregnancy, nursing, or within 1-year post-partum.
  2. Individuals who have experienced serious complications due to COVID-19 previously or during the study as determined by the investigator.
  3. Clinical diagnosis of hair loss disorder such as alopecia areata, or scarring forms of alopecia.
  4. Individuals who have had a history of any acute or chronic disease that could interfere with or increase the risk on study participation.
  5. Individuals who have had a history of any acute or chronic medical or hair condition that could affect study results, such as a history of disordered eating.
  6. Scalp hair loss on the treatment area, due to disease, injury, or medical therapy.
  7. Current skin disease (e.g., psoriasis, atopic dermatitis, skin cancer, eczema, sun damage, seborrheic dermatitis), infection, cuts, and/ or abrasions on the scalp or condition (e.g., sunburn, tattoos) on the treatment area that, in the opinion of the Investigator or qualified sub-investigator, might put the subject at risk or interfere with the study conduct or evaluations.
  8. History of surgical correction of hair loss on the scalp (i.e., hair transplant).
  9. Use of any products or devices purported to promote scalp hair growth (e.g., finasteride or minoxidil) within the 6 months prior to the Baseline Visit.
  10. Females who have recently (within the last 6 months) started the use of hormones for birth control or hormone replacement therapy (HRT). Women currently using hormones for birth control or HRT must have been on a stable dose (6 months or longer) in order to be eligible for the study (the initiation of HRT or birth control should not have been associated with the initiation of hair loss/thinning).
  11. History of malignancy (except cutaneous squamous cell carcinoma and basal cell carcinoma) or currently undergoing chemotherapy or radiation treatments.
  12. A known history of autoimmune thyroid disease, any other thyroid disorder/abnormality or other autoimmune disorders that in the opinion of the Investigator or qualified sub-investigator may interfere with the study treatment.
  13. A known history of unstable or chronic depression or bipolar disease or any other condition that may impact the subject's participation in the opinion of the investigator or qualified sub-investigator.
  14. A known allergy to any of the ingredients in the investigational product.
  15. Utilization of low-level lasers for hair growth in the last three months.
  16. Any condition that the Investigator thinks may put the subject at risk or interfere with their participation in the study or study results.
  17. Known history of or current iron deficiency, bleeding disorders or platelet dysfunction syndrome as well as subjects receiving anticoagulant therapy or smokers with usage >20 cigarettes/day as reported by the subject.
  18. Use of any medications or medicated shampoos that are known to potentially cause hair loss or affect hair growth, as determined by the Investigator or qualified sub-investigator.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Nutrafol Hair Growth Supplement

4 commercially available hair growth nutraceuticals will be evaluated. Treatment groups will be assigned according to the investigator's discretion. Efficacy comparisons will not be made across treatment groups.

Hair growth supplement for women ages 18 - 44. This product will be studied in the general women population and not postpartum women.

Hair growth supplement for women ages 18 - 44

Hair growth supplement for women ages 45 - 70

Hair growth supplement for women ages 18 - 44. This treatment group may also include subjects who do not follow a plant-based diet for purposes of extending the product claims beyond the initially studied demographic of women primarily adhering to a plant-based diet

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
The percent change in hair growth rate at Day 180 relative to baseline (Day 0)
Prazo: 180 days

The percent change in hair growth rate at Day 180 relative to baseline (Day 0) using Canfield HairMetrix® non-invasive device.

180 days

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
The percent change in hair growth rate at Day 90 relative to baseline (Day 0)
Prazo: 90 Days

The percent change in hair growth rate at Day 90 relative to baseline (Day 0) as measured by the Canfield HairMetrix®.

90 Days
The change in total hair count, terminal hairs, vellus hairs, anagen, and telogen hairs compared to baseline at 90 days
Prazo: 90 days

The change in total hair count, terminal hairs, vellus hairs, anagen, and telogen hairs compared to baseline at 90 days as measured by the Canfield HairMetrix® compared to baseline.

90 days
The change in total hair count, terminal hairs, vellus hairs, anagen, and telogen hairs compared to baseline at 180 days
Prazo: 180 days

The change in total hair count, terminal hairs, vellus hairs, anagen, and telogen hairs compared to baseline at 180 days as measured by the Canfield HairMetrix® compared to baseline.

180 days
The change in terminal to vellus ratio
Prazo: 90 Days

The change in terminal to vellus ratio as measured by the Canfield HairMetrix® at 90 days compared to baseline.

90 Days
The change in terminal to vellus ratio
Prazo: 180 Days

The change in terminal to vellus ratio as measured by the Canfield HairMetrix® at 180 days compared to baseline.

180 Days
The change in anagen to telogen ratio
Prazo: 90 Days

The change in terminal to vellus ratio per cm2 as measured by the Canfield HairMetrix® at 90 days compared to baseline.

90 Days
The change in anagen to telogen ratio
Prazo: 180 Days

The change in terminal to vellus ratio per cm2 as measured by the Canfield HairMetrix® at 180 days compared to baseline.

180 Days
The change in average number of hairs per follicular unit
Prazo: 90 Days

The change in average number of hairs per follicular unit as measured by the Canfield HairMetrix® at 90 days compared to baseline.

90 Days
The change in average number of hairs per follicular unit
Prazo: 180 Days

The change in average number of hairs per follicular unit as measured by the Canfield HairMetrix® at 180 days compared to baseline.

180 Days
The change in total hair width per cm2
Prazo: 90 Days

The change in total hair width per cm2 as measured by the Canfield HairMetrix® at 90 days compared to baseline.

90 Days
The change in total hair width per cm2
Prazo: 180 Days

The change in total hair width per cm2 as measured by the Canfield HairMetrix® at 180 days compared to baseline.

180 Days
The change in mean inter-follicular distance
Prazo: 90 Days

The change in mean inter-follicular distance as measured by the Canfield HairMetrix® at 90 days compared to baseline.

90 Days
The change in mean inter-follicular distance
Prazo: 180 Days

The change in mean inter-follicular distance as measured by the Canfield HairMetrix® at 180 days compared to baseline.

180 Days
Subjective assessments of change measured with Consumer Perception Questionnaire at 90 days
Prazo: 90 Days

Subjective assessments of change in hair growth and appearance measured with Consumer Perception Questionnaire at 90 days

90 Days
Subjective assessments of change measured with Consumer Perception Questionnaire at 180 days
Prazo: 180 Days

Subjective assessments of change in hair growth and appearance measured with Consumer Perception Questionnaire at 180 days

180 Days

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Links úteis

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

6 de maio de 2024

Conclusão Primária (Real)

18 de junho de 2025

Conclusão do estudo (Real)

18 de junho de 2025

Datas de inscrição no estudo

Enviado pela primeira vez

11 de abril de 2024

Enviado pela primeira vez que atendeu aos critérios de CQ

16 de abril de 2024

Primeira postagem (Real)

19 de abril de 2024

Atualizações de registro de estudo

Última Atualização Postada (Real)

16 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

10 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • NW-HGN-02

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .